| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Transducin-like enhancer protein 2; ESG2; |
| Entrez GeneID | 7089; |
| WB Predicted band size | 110kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human TLE2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于TLE2抗体的3-4篇模拟参考文献(基于公开研究方向的概括性描述，非真实文献)：
---
1. **文献名称**: *TLE2 as a Novel Biomarker for Ovarian Cancer Prognosis*
**作者**: Zhang Y. et al. (2020)
**摘要**: 本研究探讨了TLE2抗体在卵巢癌组织中的表达及其与患者预后的相关性。结果显示，TLE2高表达与晚期肿瘤分期和不良生存率显著相关，提示其可能作为卵巢癌的潜在预后标志物。
2. **文献名称**: *TLE2 Antibody in Differential Diagnosis of Colorectal Tumors*
**作者**: Lee S. et al. (2018)
**摘要**: 通过免疫组化分析TLE2抗体在结直肠癌和良性腺瘤中的表达差异，发现TLE2在恶性组织中表达显著升高，表明其在结直肠肿瘤良恶性鉴别诊断中的潜在应用价值。
3. **文献名称**: *Role of TLE2 in Modulating Wnt/β-catenin Signaling in Lymphoma*
**作者**: Müller R. et al. (2019)
**摘要**: 该研究利用TLE2抗体揭示TLE2蛋白通过抑制Wnt/β-catenin信号通路参与B细胞淋巴瘤的发生机制，为靶向治疗提供了理论依据。
4. **文献名称**: *TLE2 Expression Patterns in Prostate Cancer Progression*
**作者**: Gupta A. et al. (2021)
**摘要**: 通过TLE2抗体检测前列腺癌不同阶段的组织样本，发现TLE2表达随肿瘤侵袭性增加而下降，提示其可能作为抑制上皮-间质转化(EMT)的调控因子。
---
**注**：以上内容为模拟概括，实际文献需通过PubMed或Google Scholar以“TLE2 antibody”及关联关键词检索获取。TLE2(Transducin-like Enhancer of Split 2)是转录共抑制因子，研究多集中于其在癌症、发育及信号通路中的作用。
The TLE2 antibody is a tool used to detect Transducin-like enhancer of split 2 (TLE2), a member of the Groucho/Transducin-like enhancer of split (TLE) family of transcriptional corepressors. TLE proteins, including TLE2. lack DNA-binding domains but interact with transcription factors to regulate gene expression, particularly in developmental and signaling pathways such as Wnt, Notch, and Hedgehog. TLE2 is involved in repressing target genes by recruiting histone deacetylases (HDACs) and modifying chromatin structure, thereby influencing cell differentiation, proliferation, and apoptosis.
TLE2's role has been studied in embryogenesis, neurodevelopment, and cancer. Dysregulation of TLE2 is linked to tumor progression, with studies suggesting both tumor-suppressive and oncogenic roles depending on cellular context. For example, reduced TLE2 expression correlates with aggressive phenotypes in some cancers, while overexpression may drive others.
Antibodies against TLE2 enable researchers to investigate its expression patterns, subcellular localization, and interactions via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. These studies help clarify TLE2's mechanistic contributions to diseases and developmental processes. Commercial TLE2 antibodies are typically validated for specificity using knockout controls or siRNA-based silencing. However, variability in experimental conditions (e.g., tissue fixation, antibody dilution) requires careful optimization to ensure reliable results. Overall, TLE2 antibodies are vital for dissecting the multifaceted roles of TLE2 in health and disease.
×
